Financial Performance - For the three months ended June 30, 2020, the group's revenue was approximately HKD 18.8 million, a decrease of 34.8% compared to HKD 28.8 million for the same period in 2019[8]. - The group incurred a net loss of approximately HKD 4.8 million for the three months ended June 30, 2020, compared to a net profit of HKD 2.5 million for the same period in 2019[8]. - Total comprehensive loss for the period was HKD 4.8 million, compared to a total comprehensive income of HKD 2.5 million in the same period of 2019[10]. - Basic loss per share for the period was HKD (0.60), compared to earnings per share of HKD 0.31 for the same period in 2019[10]. - The group recorded a net loss of approximately HKD 4.8 million for the three months ended June 30, 2020, compared to a profit of approximately HKD 2.5 million for the same period in 2019[49]. Revenue and Income - Revenue for the three months ended June 30, 2020, was HKD 18,817,000, a decrease of 34.7% compared to HKD 28,788,000 for the same period in 2019[21]. - Revenue from treatment services was HKD 18,030,000, down 33.5% from HKD 26,964,000 in 2019[21]. - Other income increased significantly to HKD 4.0 million from HKD 0.35 million, marking an increase of 1,050% year-on-year[10]. - Other income for the three months ended June 30, 2020, was HKD 4,039,000, significantly up from HKD 352,000 in 2019[24]. - Other income increased to approximately HKD 4.0 million for the three months ended June 30, 2020, from HKD 0.4 million in the same period in 2019, primarily due to government subsidies under the anti-epidemic fund[42]. Expenses and Costs - Employee costs decreased to HKD 8.3 million from HKD 11.1 million, reflecting a reduction of 25.1% year-on-year[10]. - The total employee costs for the three months ended June 30, 2020, were HKD 8,339,000, down from HKD 11,119,000 in 2019, reflecting a reduction of 25.1%[24]. - Depreciation of property, plant, and equipment increased to HKD 2.9 million from HKD 1.9 million, representing a rise of 53.0% compared to the previous year[10]. - The depreciation expense for property, plant, and equipment increased to approximately HKD 2.9 million for the three months ended June 30, 2020, from HKD 1.9 million in the same period in 2019, due to new acquisitions[45]. - The group reported financing costs of HKD 0.474 million, a decrease from HKD 0.802 million in the previous year, indicating a reduction of 40.8%[10]. Dividends and Equity - The board of directors did not recommend the distribution of dividends for the three months ended June 30, 2020, consistent with the previous year[8]. - The group did not recommend any dividend distribution for the three months ended June 30, 2020[50]. - The group's total equity as of June 30, 2020, was HKD 34.08 million, down from HKD 70.73 million a year earlier[12]. Operational Developments - The group expanded its operations by opening new centers in Central, Causeway Bay 2, and Tsim Sha Tsui 2 to capture growing customer demand[36]. - The group plans to enhance its service offerings and increase the variety of treatments provided to strengthen its competitive advantage[36]. - The group will closely monitor market conditions and implement sustainable development strategies to overcome the current adverse environment caused by COVID-19[38]. - The impact of COVID-19 on the company's financial performance remains uncertain, with temporary closures of medical beauty centers since July 15, 2020[33]. Shareholder Information - The weighted average number of ordinary shares issued was 800,000 for both periods, with no potential ordinary shares issued[31]. - As of June 30, 2020, the company had no purchases, sales, or redemptions of its listed securities during the three months ended[57]. - The company replaced its compliance advisor from Chuangsheng Financing Limited to Qingtian Capital Limited effective May 9, 2020[58]. - Mr. Ye and Ms. Fu each hold 600,000,000 shares, representing a 75% equity interest in the company through their controlled entity, Equal Joy[60]. - Equal Joy is jointly owned by Mr. Ye and Ms. Fu, each holding a 50% beneficial interest[63]. - The company has not granted, exercised, or cancelled any share options under the share option scheme since its adoption[68]. - There are no outstanding share options, warrants, derivatives, or convertible securities as of June 30, 2020[68]. - The board of directors has not established any arrangements for directors to acquire shares or debt securities of the company[70]. - No directors or their associates have engaged in any business that competes directly or indirectly with the company[71]. - The executive directors as of the report date include Mr. Ye and Ms. Fu, with independent non-executive directors being Mr. Chan, Mr. Qiu, and Mr. Yu[72].
亮晴控股(08603) - 2021 Q1 - 季度财报